Pfizer reports that a lower dose of its COVID-19 vaccine did not produce a potent immune response in children 2 to 4. Here's what we know.
Pfizer-BioNTech announced
data from its ongoing trial of children 2 to 4 indicates that the vaccine dosage used — 3 micrograms, or one-tenth of the adult dose — did not produce a potent immune response in that group after two shots. But the two-shot regimen did produce a response — comparable to the one seen in 16-to-25-year-olds — in infants between 6 months and 2 years old. Children 5 to 11 receive a 10-microgram dose, or one-third of the formulation for people 12 and older.
Pfizer said it did not plan to test a higher dose for children under 5 at this time but will test trial subjects’ immune response after administering a third dose. “The goal here is to understand the potential of protection of the third dose,” Jerica Pitts, a spokeswoman for Pfizer,Dr. Leian Chen, the lead physician at UCLA Health Pediatrics in Marina Del Rey, says she has conversations about vaccination daily.
“I have some families who will very eagerly ask every visit” about when their younger kids might be able to get vaccinated, she said.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Covid-19: Nisra records increase in Covid-related deathsThe agency's Covid deaths total, based on mentions of the virus on death certificates, is 3,937.
Weiterlesen »
Pfizer Requests Full Approval For Covid-19 Vaccine For 12- To 15-Year-OldsThe pharmaceutical company said in November its vaccine gave the age group 100% long-term protection against the virus.
Weiterlesen »
Pfizer is testing a 3rd COVID-19 vaccine dose in young kidsPfizer and BioNTech are testing a third dose of their COVID-19 vaccine in an ongoing trial of children ages 6 months to under 5 years, the companies announced F
Weiterlesen »
Pfizer Testing Extra COVID-19 Vaccine Dose For Children Under 5The addition of an extra dose came after a preliminary analysis found 2- to 4-year-olds didn't have as strong an immune response as expected.
Weiterlesen »
Pfizer Requests Full Approval For Covid-19 Vaccine For 12- To 15-Year-OldsThe pharmaceutical company said in November its vaccine gave the age group 100% long-term protection against the virus.
Weiterlesen »
CDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’sHealth authorities said the rate of a rare but serious blood-clotting disorder associated with the Johnson & Johnson shot is higher than previously detected.
Weiterlesen »